Ascent Wealth Partners’s Boston Scientific BSX Stock Holding History

Ascent Wealth Partners’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,540	Closed	-$1.42M	–	184
2025 Q3	$1.42M	Buy	14,540 +455	+3%	+$47.1K	0.16%	106
2025 Q2	$1.51M	Buy	+14,085	New	+$1.43M	0.19%	102

Other funds holding BSX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Ascent Wealth Partners's BSX Position: Q4 2025 in Review

Ascent Wealth Partners sold out of Boston Scientific (BSX) in Q4 2025, closing a stake of 14,540 shares — an estimated $1.42M sold.

Ascent Wealth Partners first reported a position in BSX in Q2 2025 and held it in 2 quarters. The position peaked at $1.51M in Q2 2025. 1,792 funds tracked by Wall St. Rank hold BSX as of Q4 2025.

Ascent Wealth Partners reported no remaining Boston Scientific position as of Q4 2025 after selling out during the quarter.
Ascent Wealth Partners sold 14,540 Boston Scientific shares in Q4 2025, an estimated $1.42M.
Ascent Wealth Partners first reported a position in Boston Scientific in Q2 2025 and held it in 2 quarters.
Ascent Wealth Partners's Boston Scientific position peaked at $1.51M in Q2 2025.
1,792 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2025.

Based on Ascent Wealth Partners's 13F filing for Q4 2025, filed 2 Feb 2026.